Last $13.76 USD
Change Today -0.06 / -0.43%
Volume 28.0K
TNXP On Other Exchanges
As of 1:03 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

tonix pharmaceuticals holdin (TNXP) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - $21.00
52 Week Low
09/3/13 - $3.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

tonix pharmaceuticals holdin (TNXP) Related Businessweek News

No Related Businessweek News Found

tonix pharmaceuticals holdin (TNXP) Details

Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the identification and development of pharmaceutical products for the disorders of central nervous system. The company’s lead product candidate, TNX-102 sublingual tablet, is a dosage formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of episodic tension-type headache; and TNX-301 that is indicated for the treatment of alcohol abuse and dependence. The company was founded in 2007 and is headquartered in New York, New York.

6 Employees
Last Reported Date: 03/28/14
Founded in 2007

tonix pharmaceuticals holdin (TNXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $277.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $314.2K
Chief Scientific Officer, Secretary and Contr...
Total Annual Compensation: $238.2K
Compensation as of Fiscal Year 2013.

tonix pharmaceuticals holdin (TNXP) Key Developments

Tonix Pharmaceuticals Holding Corp Primary Exchange Listing will Change to Nasdaq Global Market from Nasdaq Capital Market

Effective August 11, 2014, Tonix Pharmaceuticals Holding Corp primary exchange listing will change to Nasdaq Global Market from Nasdaq Capital Market.

Tonix Pharmaceuticals Holding Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended July 30, 2014

Tonix Pharmaceuticals Holding Corp. reported unaudited consolidated earnings results for the second quarter and six months ended July 30, 2014. For the quarter, the company reported operating loss of $6,049,000, net loss of $6,044,000 or $0.61 loss per share against operating loss of $2,086,000, net loss of $2,086,000 or $0.95 loss per share for the same period a year ago. For the six months, the company reported operating loss of $11,218,000, net loss of $11,208,000 or $1.20 loss per share against operating loss of $4,087,000, net loss of $4,087,000 or $1.88 loss per share for the same period a year ago.

Tonix Pharmaceuticals Mulls Acquisitions

Tonix Pharmaceuticals Holding Corp (NasdaqCM:TNXP) is seeking acquisition opportunities. Tonix Pharmaceuticals announced a stock offering of $150 million. Tonix Pharmaceuticals intends to use the net proceeds from the sale of the securities offered by this prospectus for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, the financing of possible acquisitions or business expansions and the repayment, refinancing, redemption or repurchase of future indebtedness or capital stock.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNXP:US $13.76 USD -0.06

TNXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNXP.
View Industry Companies

Industry Analysis


Industry Average

Valuation TNXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TONIX PHARMACEUTICALS HOLDIN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at